The S stands for his being short. Those streamers with strong balance sheets will be able to cut some very aggressive deals in the next year or two. Sure some junior minors will go out but that is the norm in any high risk lending model.
I have been saying as much for 6 months bur I guess folks are in the "show me" mode. This is worth at least $2 based on the EU approval (if they sold the company) and MUCH more if FDA comes back with a reasonable trial protocal. If Prosil issues, I suspect someone larger may decide that this is worth writing a check for.
BDTB--I Feel you pain re: disappointing progress over the past three years but believe that there may be a glimmer of hope. I believe ZIOP controls access to the rheoswitch in oncology. Rental of same to third parties may be a way to create some non-dilutive financing down the road. Also, they publically stated that several new oncology indications will be rolled out. How do you do execute on that promise with 20 persons and a limited budget? My bet is we FINALLY get the long discussed partnering event. I think Kirk was asumming a Pali sale could fund this for the next 5 years but has now had to re-examine the options. Kirk neeeds a significant partnering to back one of his ECCs or at some point Intrexon shares will come under pressure. 2Billion XON valuation is generous unless there is something behind the curtain unbeknownest to public investors.
I believe Kirk figures this out eventually but am unsure if that happens in 6 months or 3 years. I really wish he would put Dr. Broder on BOD. Why do we still have VCs from the Lindsey Rosenwald era???? At least moving Broder in would signal to folks how important this oncology ECC is to the mothership and its captain.
"they have the early lead as far as DNA technology for cancer cures"---Very hard to ascertain from the outside. ZIOP/Intrexon pairing is coming up on its 3 year anniversary. I had hoped that they would be farther down the road toward making some substantive progress. I guess everything in oncology takes far longer and costs far more than anticipated.
We'll see. At a minimum the granting of a patent could help them down the road if negotiation a deal in EU.If CRMD teams up with one of the big boys, the guys at TP will be in a very tight place. The TP guys always thought CRMD would go bankrupt and the IP infractions would magically disappear. Time is now on CRMD's side. If there is no peaceful resolution, I would love to see Elliot unleash their dogs of war upon the interlopers. Once CRMD spends the time and money on lawyers, there is less of a likelihood settling.
Of course they do. My simple point was that this has nothing to do with Aegis making an investment. It was a transaction and (of course) increasing the size of the transaction increases their compensation. Kirk has now put gas in the tank of virtually all of his ECCs. Hopefully one or more bear fruit in 2015.
Greenshoe is used to cover CUSTOMER overallotments . Aegis is not buying the stock!
Kirk has a decade long view on most things. Remember, there has to be an outside appetite for the stock to do a raise at the current PPS. I am not sure if SYN has much of a following left on Wall Street. It is akin to a private placement with a stock symbol. Maybe the discount is simply the price for having a willing backstop behind the company.
Same pattern with ZIOP, same pattern with FSCS. Kirk picks the price. It is his world. None of these ECCs could raise a dime without him here.
Agree. Sales slows burn rate and optens up options. FDA info coming shortly. Tauropharm situation is also a wild card to the upside. Why folks would sell the news is beyond me but let those who want to exit.
Kirk needs a win with one of his ECCs. ZIOP is the best candidate but if the breast data this weekend is not compelling, XON will trade down in sympaty. Great long term story here but I am not sure if it justifies a 2 Billion market cap if there are no short term value drivers on the horizon. Fingers crossed on the breast data but not expected anything earth shaking.
Stopped trying to figure the day to day here a long time a go. The only question is wheter or not Pali is dead and if so, what is the speed/cost of building out the synthetic platform. I guess the breast data will answer the first question.
Web-site upgrade, more dog and ponies, polished power-point deck--all good but essentially meaningless in the short term. Milby and Co. need to execute on the sales front ASAP. We were 6 months late getting approval and now we are 5 months later with not a single Euro deposited into the till. It seems they made some progress on the FDA side but I see nothing that is obvious on the partnering front. If CRMD team was assuming approval Dec 2012, you would thing they would have at least had some preliminary discussions with potential marketing partners in the middle east and/or Asia. I am not sure how much rope Elliot is willing to give CRMD. Time to execute or hand it over to a larger, deeper pocketed entity that is able. I think Elliot gives them 90 days grace at the most. If there is little progress this will become a transactional event. That would be a shame given how much effort was made to procure additional runway. Hats off to CFO Lefkowitz/CSO Pfaffle---those guys functioned as defacto investment bankers and bought us some room. Now it is up to others not to squander their prodigious efforts.
I think, to be fair, both the melanoma and breast data sets are pretty immature. I think brain cancer could be the shortest patway of the 3 cancer programs(melanoma, breast, brain ).
Well, at least we have continued affirmation that the rheoswitch works. I am very interested in the breast data since (I believe) this was the rrial in which ZIOP paired the old small molecule technology with IL12.
I am finally resigned to the idea that SCLC was nothing but a long shot from the get go. If we don't see anything significant from Pali in breast, and without Pali data from PICASSO III in hand, we must simply assume that was a 6 year dead end.
Still hopeful we see something shorter term in the brain cancer space.